{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:17:20Z","timestamp":1793146640828,"version":"4.5.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bimekizumab, a humanized monoclonal antibody, exerts its therapeutic effect by inhibiting interleukin-17A\/F and is indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients. However, the long-term safety profile of bimekizumab remains under evaluation. In this study, adverse events were analyzed using data from the US Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed adverse event reports in FAERS from the third quarter of 2021 to the fourth quarter of 2024, with bimekizumab identified as the primary suspected drug. The analytical methods included the Reported Odds Ratio, Proportional Reporting Ratio, Bayesian Confidence Propagation Neural Network, and Multi-Item Gamma Poisson Shrinker.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 2,744 suspected adverse event cases with bimekizumab as the major suspected drug were collected from the FAERS database in this study. The results showed that common clinical adverse events of bimekizumab included injection site pain, fatigue, pruritus, headache, arthralgia, rash, pain, oesophageal candidiasis, diarrhea. In addition, we detected probable unexpected adverse events using disproportionality analysis, such as depression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We identified potential new adverse events associated with bimekizumab through disproportionate analysis of extensive real-world data from the FAERS database. These findings enable healthcare professionals and pharmacists to prioritize effective management of high-risk adverse events, optimize drug utilization in clinical settings, and enhance patient medication safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1714173","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T06:38:42Z","timestamp":1767595122000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for bimekizumab"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhuomiao","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xihui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiqing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/s13555-022-00760-8","article-title":"Efficacy of bimekizumab and other biologics in moderate to severe plaque psoriasis: a systematic literature review and a network meta-analysis","volume":"12","author":"Armstrong","year":"2022","journal-title":"Dermatol Ther. (Heidelb)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/bjd.17403","article-title":"Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients","volume":"181","author":"Augustin","year":"2019","journal-title":"Br. J. Dermatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"621956","DOI":"10.3389\/fimmu.2021.621956","article-title":"Major role of the IL17\/23 axis in psoriasis supports the development of new targeted therapies","volume":"12","author":"Bugaut","year":"2021","journal-title":"Front. Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1111\/j.1365-2133.2010.10196.x","article-title":"Juvenile psoriasis in European and Asian children: similarities and differences","volume":"164","author":"Chiam","year":"2011","journal-title":"Br. J. Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1124628","DOI":"10.3389\/fphar.2023.1124628","article-title":"IL-17 inhibitor-associated inflammatory bowel disease: a study based on literature and database analysis","volume":"14","author":"Deng","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1349636","DOI":"10.3389\/fimmu.2024.1349636","article-title":"Major cardiovascular events under biologic psoriasis therapies: a 19-year real-world analysis of FAERS data","volume":"15","author":"Ding","year":"2024","journal-title":"Front. Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1097\/MIB.0000000000001169","article-title":"Prevalence and phenotype of concurrent psoriasis and inflammatory bowel disease","volume":"23","author":"Eppinga","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/muscles4030026","article-title":"Mechanisms underlying muscle-related diseases and aging: insights into pathophysiology and therapeutic strategies","volume":"4","author":"Fan","year":"2025","journal-title":"Muscles"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.2020-2-1","article-title":"Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors","volume":"9","author":"Fieldhouse","year":"2020","journal-title":"Drugs Context"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1007\/s40265-021-01612-z","article-title":"Bimekizumab for the treatment of psoriasis","volume":"81","author":"Freitas","year":"2021","journal-title":"Drugs"},{"key":"B11","doi-asserted-by":"publisher","first-page":"eaau4594","DOI":"10.1126\/sciimmunol.aau4594","article-title":"Regulation of host-microbe interactions at oral mucosal barriers by type 17 immunity","volume":"5","author":"Gaffen","year":"2020","journal-title":"Sci. Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.1093\/rheumatology\/keaa189","article-title":"Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials","volume":"59","author":"Genovese","year":"2020","journal-title":"Rheumatol. Oxf."},{"key":"B13","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/jid.2011.304","article-title":"A phase III, randomized, controlled trial of the fully human IL-12\/23 mAb briakinumab in moderate-to-severe psoriasis","volume":"132","author":"Gordon","year":"2012","journal-title":"J. Invest Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1056\/NEJMc2113092","article-title":"Bimekizumab versus adalimumab in plaque psoriasis","volume":"385","author":"Griffith","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.cytogfr.2022.07.005","article-title":"The involvement of TH17 cells in the pathogenesis of IBD","volume":"69","author":"Jiang","year":"2023","journal-title":"Cytokine Growth Factor Rev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.gtc.2020.07.001","article-title":"Ulcerative colitis: making the diagnosis","volume":"49","author":"Kaenkumchorn","year":"2020","journal-title":"Gastroenterol. Clin. North Am."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2119767","DOI":"10.1080\/21645515.2022.2119767","article-title":"Review of bimekizumab in the treatment of psoriasis","volume":"18","author":"Koppu","year":"2022","journal-title":"Hum. Vaccin Immunother."},{"key":"B19","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/bjd.18245","article-title":"Management of psoriasis as a systemic disease: what is the evidence?","volume":"182","author":"Korman","year":"2020","journal-title":"Br. J. Dermatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s13555-020-00472-x","article-title":"Two-Year US pharmacovigilance report on brodalumab","volume":"11","author":"Lebwohl","year":"2021","journal-title":"Dermatol Ther. (Heidelb)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1016\/j.jid.2024.05.015","article-title":"Paradoxical psoriasis: an updated review of clinical features, pathogenesis, and treatment options","volume":"144","author":"Maronese","year":"2024","journal-title":"J. Invest Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1007\/s13555-024-01295-w","article-title":"Bimekizumab efficacy in high-impact areas: pooled 2-Year analysis in Scalp, nail, and palmoplantar psoriasis from phase 3\/3b randomized controlled trials","volume":"14","author":"Merola","year":"2024","journal-title":"Dermatol Ther. (Heidelb)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"103910","DOI":"10.1016\/j.autrev.2025.103910","article-title":"The role of mTOR signaling pathway in systemic lupus erythematosus and systemic vasculitis","volume":"24","author":"Michailidou","year":"2025","journal-title":"Autoimmun. Rev."},{"key":"B24","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2147\/ITT.S240891","article-title":"The role of IL-17 cytokines in psoriasis","volume":"10","author":"Mosca","year":"2021","journal-title":"Immunotargets Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/bjd.21827","article-title":"Using the upgrade criteria of the European Psoriasis Consensus is best practice care according to the people-centred healthcare concept of the World Health Organization","volume":"187","author":"Mrowietz","year":"2022","journal-title":"Br. J. Dermatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3238\/arztebl.m2024.0064","article-title":"Psoriasis as a systemic disease","volume":"121","author":"Mrowietz","year":"2024","journal-title":"Dtsch. Arztebl Int."},{"key":"B27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/nyas.12059","article-title":"Role of PI3K\/Akt and mTOR complexes in Th17 cell differentiation","volume":"1280","author":"Nagai","year":"2013","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/1346-8138.14941","article-title":"Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: results from the SustaIMM phase 2\/3 trial","volume":"46","author":"Ohtsuki","year":"2019","journal-title":"J. Dermatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s13555-025-01361-x","article-title":"Indirect comparison between bimekizumab and Brodalumab for the management of moderate to severe psoriasis: a 36-Week real-life Study","volume":"15","author":"Potestio","year":"2025","journal-title":"Dermatol Ther. (Heidelb)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1001\/2013.jamapsychiatry.4","article-title":"A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers","volume":"70","author":"Raison","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"B31","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"","journal-title":"N. Engl. J. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2147\/PTT.S367744","article-title":"Bimekizumab for the treatment of psoriasis: a review of the Current knowledge","volume":"12","author":"Ruggiero","year":"2022","journal-title":"Psoriasis (Auckl)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/bjd.14964","article-title":"Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials","volume":"176","author":"Rungapiromnan","year":"2017","journal-title":"Br. J. Dermatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1080\/14740338.2024.2399092","article-title":"Treatment-emergent Candida infections in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis treated with ixekizumab: an integrated safety analysis of 25 clinical studies","volume":"23","author":"Schwartzman","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"B36","doi-asserted-by":"publisher","first-page":"12793","DOI":"10.3390\/ijms222312793","article-title":"The cytokine mediated molecular pathophysiology of psoriasis and its clinical implications","volume":"22","author":"Singh","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e199","DOI":"10.1038\/tp.2012.120","article-title":"Evidence for sustained elevation of IL-6 in the CNS as a key contributor of depressive-like phenotypes","volume":"2","author":"Sukoff Rizzo","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"B38","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.ad.2017.02.005","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis: subgroup analysis of Latin American patients in the phase 3 randomized UNCOVER-3 study","volume":"108","author":"Valenzuela","year":"2017","journal-title":"Actas Dermosifiliogr."},{"key":"B39","doi-asserted-by":"publisher","first-page":"127930","DOI":"10.1016\/j.micres.2024.127930","article-title":"Emerging concepts in mucosal immunity and oral microecological control of respiratory virus infection-related inflammatory diseases","volume":"289","author":"Wang","year":"2024","journal-title":"Microbiol. Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus Adalimumab in plaque psoriasis","volume":"385","author":"Warren","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1007\/s13555-024-01302-0","article-title":"Long-Term efficacy and safety of Bimekizumab and other biologics in moderate to severe plaque psoriasis: updated systematic literature review and network meta-analysis","volume":"14","author":"Warren","year":"2024","journal-title":"Dermatol Ther. (Heidelb)"},{"key":"B42","doi-asserted-by":"publisher","first-page":"699848","DOI":"10.3389\/fimmu.2021.699848","article-title":"Depression and obesity in patients with psoriasis and psoriatic arthritis: is IL-17-Mediated immune dysregulation the connecting link?","volume":"12","author":"Zafiriou","year":"2021","journal-title":"Front. Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"781","DOI":"10.3390\/cells13090781","article-title":"Nuclear mTOR signaling orchestrates transcriptional programs underlying cellular growth and metabolism","volume":"13","author":"Zhao","year":"2024","journal-title":"Cells"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1473356","DOI":"10.3389\/fmed.2024.1473356","article-title":"Effectiveness, quality of life, and safety of secukinumab versus conventional systemic therapy in patients with erythrodermic psoriasis: a comparative study","volume":"11","author":"Zhou","year":"2024","journal-title":"Front. Med. (Lausanne)"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1714173\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T06:38:43Z","timestamp":1767595123000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1714173\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":44,"alternative-id":["10.3389\/fphar.2025.1714173"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1714173","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"article-number":"1714173"}}